RVLPQ
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q2 | -0.24 | $8M | -$13M |
| 2023 Q1 | -0.12 | $9M | -$7M |
| 2022 Q4 | -0.18 | $10M | -$17M |
| 2022 Q3 | -0.16 | $10M | -$10M |
| 2022 Q2 | -0.14 | $8M | $2M |
| 2022 Q1 | -0.08 | $21M | -$13M |
| 2021 Q4 | -0.24 | $3M | -$25M |
| 2021 Q3 | -0.28 | $2M | -$16M |